Search Result

Results for "

HBV Inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	HBV (108) Antibiotic (1) Apoptosis (7) Autophagy (3) Bacterial (2) Bcl-2 Family (1) Carbonic Anhydrase (1) Cytochrome P450 (1) DNA/RNA Synthesis (12) Endogenous Metabolite (3) Estrogen Receptor/ERR (1) Ferroptosis (1) Fungal (1) HCV (4) Histamine Receptor (1) HIV (20) IKK (2) Influenza Virus (2) Isotope-Labeled Compounds (4) Lipoxygenase (1) NADPH Oxidase (1) Organoid (1) Orthopoxvirus (2) Parasite (3) PROTACs (1) Pyroptosis (1) Reactive Oxygen Species (3) Reverse Transcriptase (11) SARS-CoV (1) Sirtuin (3) Small Interfering RNA (siRNA) (1)
By Research Areas:	Cancer (15) Cardiovascular Disease (1) Endocrinology (1) Infection (110) Inflammation/Immunology (8) Metabolic Disease (3) Neurological Disease (3)
Click Chemistry:	Azide (4) Alkynes (1)

122

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: HBV

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-155968

HBV-IN-40

HBV Infection

HBV-IN-40 (Compound 11826096) is a HBV inhibitor (IC₅₀: 0.7 μM). HBV-IN-40 is an antiviral agent .

HBV-IN-40	HBV	Infection
HBV-IN-40 (Compound 11826096) is a HBV inhibitor (IC₅₀: 0.7 μM). HBV-IN-40 is an antiviral agent .

HY-161327

HBV-IN-44	HBV	Infection
HBV-IN-44 (Compound (S)-2a) is a *HBV* inhibitor with a IC₅₀ value of 23 nM for HbsAg. HBV-IN-44 is less toxic to the neurite growth of HT22 cells and DRG neurons in vitro .

HY-N4168A

Neochlorogenic acid methyl ester 5-O-Caffeoylquinic acid methyl ester	HBV	Infection Cancer
Neochlorogenic acid methyl ester (5-O-Caffeoylquinic acid methyl ester) is an *HBV* inhibitor. Neochlorogenic acid methyl ester can be isolated from L. japonica flower buds with potent HBV inhibitory activity .

HY-157993

SAG-524	HBV	Infection
SAG-524 is a potent oral small molecule *HBV* viral replication inhibitor. SAG-524 decreased HBV-DNA and HbsAg levels in supernatant of HepG2.2.15 cells, IC₅₀ 0.92 and 1.4 nM, respectively .

HY-N3609

Coclauril

HBV Infection

Coclauril is an inhibitor of HBV. Coclauril inhibits HBV replication in the human hepatoblastoma cell line with an EC₅₀ of 7.6 μg/mL .

Coclauril	HBV	Infection
Coclauril is an inhibitor of *HBV. Coclauril inhibits* HBV replication in the human hepatoblastoma cell line with an EC₅₀ of 7.6 μg/mL .

HY-N2882

Apigenin-4'-α-L-rhamnoside	HBV	Infection
Apigenin-4'-α-L-rhamnoside is a potent inhibitor of *HBV. Apigenin-4'-α-L-rhamnoside inhibits* the secretory level of HBV surface antigen (HBsAg) in HepG2.2.15 cells .

HY-145713

HBV-IN-19	HBV	Infection
HBV-IN-19 inhibits hepatitis B virus (HBV) infection. Inhibiting HBsAg secretion and/or production is a strategy for the treatment of HBV infection, including chronic HBV infection .

HY-145713A

HBV-IN-19 TFA	HBV	Infection
HBV-IN-19 TFA inhibits hepatitis B virus (HBV) infection. Inhibiting HBsAg secretion and/or production is a strategy for the treatment of HBV infection, including chronic HBV infection .

HY-146395

HBV-IN-23	HBV DNA/RNA Synthesis Apoptosis	Infection Cancer
HBV-IN-23 (Compound 5k) is an inhibitor of HBV DNA replication with an IC₅₀ of 0.58 μM. HBV-IN-23 inhibits HBV DNA replication in both agent sensitive and resistant HBV strains. HBV-IN-23 shows anti-hepatocellular carcinoma cell (HCC) activities. HBV-IN-23 induces HepG2 cells apoptosis .

HY-N12483

Catenulopyrizomicin A	HBV	Infection
Catenulopyrizomicin A has a thiazolyl pyridine moiety. Catenulopyrizomicin A can be isolated from the fermentation broth of rare actinomycete Catenuloplanes sp. Catenulopyrizomicin A has anti-Hepatitis B virus activity .

HY-149392

HBV-IN-35

HBV Infection

HBV-IN-35 (Compound 88) is a HBV inhibitor. HBV-IN-35 has anti-HBV activities in mouse and human hepatocytes (EC₅₀: 100 nM and 400 nM respectively) .
HY-149815

HBV-IN-33

HBV Infection Inflammation/Immunology

HBV-IN-33 (C-49), a HBV inhibitor, notably suppresses HBV replication in HepAD38, HepG2-HBV1.3 and HepG2-NTCP cells .

HBV-IN-35	HBV	Infection
HBV-IN-35 (Compound 88) is a *HBV* inhibitor. HBV-IN-35 has anti-HBV activities in mouse and human hepatocytes (EC₅₀: 100 nM and 400 nM respectively) .

HBV-IN-33	HBV	Infection Inflammation/Immunology
HBV-IN-33 (C-49), a *HBV* inhibitor, notably suppresses HBV replication in HepAD38, HepG2-HBV1.3 and HepG2-NTCP cells .

HY-149357

Yhhu6669	HBV	Infection
Yhhu6669 is an anti-HBV agent. Yhhu6669 inhibits HBV DNA. Yhhu6669 inhibits HBV replication by inducing the formation of DNA-free capsids. Yhhu6669 decreases HBV DNA and HBcAg in AAV/HBV-infected mice. Yhhu6669 has favorable PK properties .

HY-156703S

HBV-IN-39-d3	HBV	Infection
HBV-IN-39-d3 (Example 14) is a deuterated HBV-IN-39 (Example 13). HBV-IN-39 is an HBV inhibitor. HBV-IN-39-d3 has better oral bioavailability than HBV-IN-39 .

HY-148782

HBV-IN-31	HBV	Infection
HBV-IN-31 is a potent cccDNA (covalently closed circular DNA) inhibitor. HBV-IN-31 shows anti-HBV activity with an IC₅₀ value of 0.13 µM for HBsAg. HBV-IN-31 inhibits cell growth .

HY-148783

HBV-IN-32	HBV	Infection
HBV-IN-32 is a potent cccDNA (covalently closed circular DNA) inhibitor. HBV-IN-32 shows anti-HBV activity with an IC₅₀ value of 0.14 µM for HBsAg. HBV-IN-32 inhibits cell growth .

HY-163124

HBV-IN-43

HBV Infection

HBV-IN-43 (compound 5832) is a potent inhibitor of HBV .
HY-156665

HBV-IN-37

HBV Infection

HBV-IN-37 is an inhibitor of HBV with an EC₅₀ value of 10 μM .

HBV-IN-43	HBV	Infection
HBV-IN-43 (compound 5832) is a potent inhibitor of *HBV* .

HBV-IN-37	HBV	Infection
HBV-IN-37 is an inhibitor of *HBV* with an EC₅₀ value of 10 μM .

HY-131343

HBV-IN-4	HBV DNA/RNA Synthesis	Infection
HBV-IN-4, a phthalazinone derivative, is a potent and orally active HBV DNA replication inhibitor with an IC₅₀ of 14 nM. HBV-IN-4 induces the formation of genome-free capsids and has potent anti-HBV potencies .

HY-156702

HBV-IN-38

HBV Infection

HBV-IN-38 (Example 193) is an HBV DNA inhibitor (EC₅₀≤100nM). HBV-IN-38 can be used to study viral infections .

HBV-IN-38	HBV	Infection
HBV-IN-38 (Example 193) is an *HBV* DNA inhibitor (EC₅₀≤100nM). HBV-IN-38 can be used to study viral infections .

HY-155547

HBV-IN-34	HBV	Infection
HBV-IN-34 (compound 17i) is a potent HBsAg production inhibitor. HBV-IN-34 exhibits excellent in vitro anti-HBV potency, with an EC₅₀ of 0.018 μM and 0.044 μM for HBV DNA and HBsAg, respectively .

HY-146011

HBV-IN-21	HBV DNA/RNA Synthesis	Infection
HBV-IN-21 (Compound II-8b) is an HBV DNA replication inhibitor with an IC₅₀ of 2.2 µM. HBV-IN-21 can interact HBV 4 capsid protein with good affinity (K_D = 60.0 μM) .

HY-145872

HBV-IN-20

HBV Infection

HBV-IN-20 is a potent and oral active HBV inhibitor with an EC₅₀ of 0.46 µM. HBV-IN-20 is a typical type II CpAM (core protein assembly modulators) .
HY-145049

HBV-IN-6

HBV Infection

HBV-IN-6 is a potent HBV inhibitor with an EC₅₀ of 44 nM (WO2021213445A1, compound 3) .
HY-145050

HBV-IN-7

HBV Infection

HBV-IN-7 is a potent HBV inhibitor with an EC₅₀ of 7 nM (WO2021213445A1, compound 5) .
HY-149476

5-LOX-IN-5

Lipoxygenase Neurological Disease

5-LOX-IN-5 (Compound 29) is a 5-LOX inhibitor (IC₅₀: 56 nM). 5-LOX-IN-5 can be used for research of neurodegenerative diseases .
HY-145051

HBV-IN-8

HBV Infection

HBV-IN-8 is a potent HBV inhibitor with an EC₅₀ of 287.9 nM (WO2021213445A1, compound 13) .

HBV-IN-20	HBV	Infection
HBV-IN-20 is a potent and oral active *HBV* inhibitor with an EC₅₀ of 0.46 µM. HBV-IN-20 is a typical type II CpAM (core protein assembly modulators) .

HBV-IN-6	HBV	Infection
HBV-IN-6 is a potent *HBV* inhibitor with an EC₅₀ of 44 nM (WO2021213445A1, compound 3) .

HBV-IN-7	HBV	Infection
HBV-IN-7 is a potent *HBV* inhibitor with an EC₅₀ of 7 nM (WO2021213445A1, compound 5) .

5-LOX-IN-5	Lipoxygenase	Neurological Disease
5-LOX-IN-5 (Compound 29) is a *5-LOX inhibitor* (IC₅₀: 56 nM). 5-LOX-IN-5 can be used for research of neurodegenerative diseases .**

HBV-IN-8	HBV	Infection
HBV-IN-8 is a potent *HBV* inhibitor with an EC₅₀ of 287.9 nM (WO2021213445A1, compound 13) .

HY-117650A

RG7834 3 Publications Verification RO 7020322	HBV	Infection
RG7834 (RO 7020322) is a highly selective and orally bioavailable *HBV* inhibitor, potently inhibits HBV antigens (both HBsAg and HBeAg) and HBV DNA, with IC₅₀s of 2.8, 2.6, and 3.2 nM, respectively, in dHepaRG Cells .

HY-148348

AB-836

HBV Infection

AB-836 is an orally active HBV capsid inhibitor. AB-836 inhibits viral replication by interacting with HBV core protein .

AB-836	HBV	Infection
AB-836 is an orally active *HBV* capsid inhibitor. AB-836 inhibits viral replication by interacting with HBV core protein .

HY-147863

HBV-IN-24	HBV	Infection Neurological Disease
HBV-IN-24 (compound (2ʹS, 6S)-1a) is a potent *HBV* inhibitor. HBV-IN-24 exhibits potent inhibition activity against HBV DNA, HBsAg, and HBeAg, with EC₅₀ values of 0.6, 0.6, and 4.6 nM, respectively. HBV-IN-24 shows excellent antiviral activity, could have improved neurotoxicity .

HY-146394

HBV-IN-22	HBV DNA/RNA Synthesis	Infection
HBV-IN-22 (Compound LC5f) is an inhibitor of HBV DNA replication with IC₅₀ values of 0.71 μM and 0.84 μM against wild-type and agent resistant HBV strains, respectively .

HY-P3465

Bulevirtide Myrcludex B	HBV	Infection
Bulevirtide (Myrcludex B) is a NTCP inhibitor, a linear lipopeptide of 47 amino acids. Bulevirtide inhibits HBV and HDV entry into liver cells, blocks HBV infection in hepatocytes, and participates in HBV transcriptional suppression. Bulevirtide can be used in HDV infection and compensated cirrhosis research .

HY-145052

HBV-IN-9	HBV	Infection
HBV-IN-9 is a potent HBsAg (HBV Surface antigen) inhibitor (IC₅₀=10 nM) and HBV DNA production inhibitor (IC₅₀=0.15 nM in HepG2.2.15 cells) . From patent WO2018001952A1, example 20.

HY-N10404

Junceellolide C	HBV	Inflammation/Immunology
Junceellolide C is a transcription inhibitor of cccDNA. Junceellolide C inhibits *HBV* DNA replication and significantly decreases the level of supernatant *HBV* RNA with EC₅₀ values of 5.19, 3.52 μM respectively in HepAD38 cells. Junceellolide C is a potent anti-HBV agent .

HY-145871

BA38017

HBV Infection

BA38017 is a potent HBV core protein assembly modulator. BA38017 inhibits HBV replication with an EC₅₀ of 0.20 μM .

BA38017	HBV	Infection
BA38017 is a potent HBV core protein assembly modulator. BA38017 inhibits HBV replication with an EC₅₀ of 0.20 μM .

HY-144047

HBV-IN-16	HBV DNA/RNA Synthesis	Infection
HBV-IN-16 is a potent inhibitor of covalently closed circular DNA (cccDNA). cccDNA serves as the template for viral RNA transcription and subsequent viral DNA generation. HBV-IN-16 is a quinoline derivative. HBV-IN-16 has the potential for the research of HBV infection (extracted from patent WO2019121357A1, compound 1) .

HY-144045

HBV-IN-14	HBV DNA/RNA Synthesis	Infection
HBV-IN-14 is a potent inhibitor of covalently closed circular DNA (cccDNA). cccDNA serves as the template for viral RNA transcription and subsequent viral DNA generation. HBV-IN-14 is a pyridinopyrimidinones compound. HBV-IN-14 has the potential for the research of HBV infection (extracted from patent WO2021190502A1, compound 5) .

HY-144046

HBV-IN-15	HBV DNA/RNA Synthesis	Infection
HBV-IN-15 is a potent inhibitor of covalently closed circular DNA (cccDNA). cccDNA serves as the template for viral RNA transcription and subsequent viral DNA generation. HBV-IN-15 is a flavone derivative. HBV-IN-16 has the potential for the research of HBV infection (extracted from patent WO2020052774A1, compound 2) .

HY-156272

HBV-IN-41

HBV Infection

HBV-IN-41 (compound 45) is a potent and orally active Hepatitis B Virus (HBV) inhibitor, with an EC₅₀ of 0.027μM .

HBV-IN-41	HBV	Infection
HBV-IN-41 (compound 45) is a potent and orally active Hepatitis B Virus (HBV) inhibitor, with an EC₅₀ of 0.027μM .

HY-148768

AB-506	HBV	Inflammation/Immunology
AB-506 is an orally active inhibitor of *HBV* replication targeting the viral core protein. AB-506 can bind to HBV core protein, accelerate capsid assembly and inhibit HBV pgRNA encapsidation. AB-506 can be used in chronic hepatitis B (CHB) research .

HY-W676876

Oxynitidine	HBV	Infection
Oxynitidine is an *HBV* inhibitor (ID₅₀=30.8 µg/mL), which can effectively inhibit the DNA replication activity of HBV. Oxynitidine can be used in the study of viral infections .

HY-148781

HBV-IN-30	HBV	Infection
HBV-IN-30 (ex44), a flavone derivative, is a potent covalently closed circular DNA (cccDNA) inhibitor. cccDNA serves as the template for viral RNA transcription and subsequent viral DNA generation. HBV-IN-30 has the potential for the research of HBV infection .

HY-148780

HBV-IN-29	HBV	Infection
HBV-IN-29 (ex8), a flavone derivative, is a potent covalently closed circular DNA (cccDNA) inhibitor. cccDNA serves as the template for viral RNA transcription and subsequent viral DNA generation. HBV-IN-29 has the potential for the research of HBV infection .

HY-14844

Lagociclovir MIV-210	HBV	Infection
Lagociclovir (FLG) is a nucleoside analogue that inhibits wild-type hepatitis B virus (HBV) replication in a human hepatoma cell line permanently expressing HBV .

HY-100028

AT-130 1 Publications Verification
AT-130, a phenylpropenamide derivative, is a potent hepatitis B virus (HBV) replication non-nucleoside inhibitor. AT-130 inhibits the viral DNA synthesis with an EC₅₀ of 0.13 μM. AT-130 inhibits both wt and mutant HBVs. AT-130 has anti-HBV activity in hepatoma cells .

HY-122209

DVR-01	HBV	Infection
DVR-01 is a *HBV* inhibitor with EC₅₀ values of 1.7 and 1.6 μM in AML12HBV10 and HepDES19 cells, respectively. DVR-01 shows antiviral activity against drug-resistant HBV mutants with EC₅₀s of 2.403-3.273 μM. DVR-01 can be used for the research of HBV infection and related diseases .

HY-113904S

(Rac)-Tenofovir-d6	Reverse Transcriptase HIV HBV	Infection
(Rac)-Tenofovir-d₆ is a labelled racemic Tenofovir. Tenofovir (GS 1278) is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B (HBV)[1].

HY-112142

AB-423 3 Publications Verification	HBV	Infection
AB-423 is an inhibitor of HBV capsid assembly, and potent inhibits HBV replication with EC₅₀/EC₉₀ of 0.08-0.27 μM/0.33-1.32 μM in cells.

HY-127122

Valtorcitabine dihydrochloride

HBV Infection

Valtorcitabine dihydrochloride is a prodrug of L-deoxycytidine and also is an HBV inhibitor .

HY-116999

IR415	HBV	Infection
IR415 is a potent *anti-HBV* agent** and inhibits HBV replication by blocking the HBx activity. IR415 selectively interacts with HBx (K_d=2 nM) and blocks HBV-mediated RNAi suppression, reverses the inhibitory effect of HBx protein on the activity of the dicer endoribonuclease . HBx: hepatitis B virus X protein.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N4168A

Neochlorogenic acid methyl ester 5-O-Caffeoylquinic acid methyl ester	Structural Classification Caprifoliaceae Lonicera japonica Thunb. Source classification Phenols Polyphenols Plants	HBV
Neochlorogenic acid methyl ester (5-O-Caffeoylquinic acid methyl ester) is an *HBV* inhibitor. Neochlorogenic acid methyl ester can be isolated from L. japonica flower buds with potent HBV inhibitory activity .

HY-N3609

Coclauril	Structural Classification Natural Products Cinnamomum subavenium Miq. Source classification Rhizophoraceae Bruguiera gymnorhiza (Linnaeus) Savigny Plants Lauraceae	HBV
Coclauril is an inhibitor of *HBV. Coclauril inhibits* HBV replication in the human hepatoblastoma cell line with an EC₅₀ of 7.6 μg/mL .

HY-N2882

Apigenin-4'-α-L-rhamnoside	Ranunculus sieboldii Miq. Structural Classification Flavonoids Flavones Source classification Ranunculaceae Plants	HBV
Apigenin-4'-α-L-rhamnoside is a potent inhibitor of *HBV. Apigenin-4'-α-L-rhamnoside inhibits* the secretory level of HBV surface antigen (HBsAg) in HepG2.2.15 cells .

HY-N12483

Catenulopyrizomicin A	Structural Classification Alkaloids Microorganisms Source classification Pyridine Alkaloids	HBV
Catenulopyrizomicin A has a thiazolyl pyridine moiety. Catenulopyrizomicin A can be isolated from the fermentation broth of rare actinomycete Catenuloplanes sp. Catenulopyrizomicin A has anti-Hepatitis B virus activity .

HY-N10404

Junceellolide C	Classification of Application Fields Animals Terpenoids Source classification Diterpenoids Inflammation/Immunology Disease Research Fields	HBV
Junceellolide C is a transcription inhibitor of cccDNA. Junceellolide C inhibits *HBV* DNA replication and significantly decreases the level of supernatant *HBV* RNA with EC₅₀ values of 5.19, 3.52 μM respectively in HepAD38 cells. Junceellolide C is a potent anti-HBV agent .

HY-W676876

Oxynitidine	Structural Classification Alkaloids Other Alkaloids Source classification Rutaceae Zanthoxylum nitidum (Roxb.) DC. Plants	HBV
Oxynitidine is an *HBV* inhibitor (ID₅₀=30.8 µg/mL), which can effectively inhibit the DNA replication activity of HBV. Oxynitidine can be used in the study of viral infections .

HY-N12105

Dihydrodehydrodiconiferyl alcohol 9-O-β-D-xylopyranoside	Structural Classification Source classification Lignans Phenylpropanoids Plants Schisandraceae Illicium henryi Diels.	HBV
Dihydrodehydrodiconiferyl alcohol 9-O-β-D-xylopyranoside is an anti-hepatitis B virus (anti-HBV) agent. Dihydrodehydrodiconiferyl alcohol 9-O-β-D-xylopyranoside inhibits HBV surface antigen (HBsAg) and HBV e antigen (HBeAg) secretion on Hep G2.2.15 cell line, with IC₅₀ values of 1.67 and >2.15 mM, respectively .

HY-N0054

Osthole 10+ Cited Publications Osthol; NSC 31868	Cardiovascular Disease Structural Classification Classification of Application Fields Source classification Coumarins Plants Biological Pesticide Research Agricultural Research Infection other families Phenylpropanoids Inflammation/Immunology Disease Research Fields Endocrinology	Histamine Receptor Apoptosis Parasite HBV
Osthole (Osthol) is a natural antihistamine alternative. Osthole may be a potential inhibitor of histamine H₁ receptor activity. Osthole also suppresses the secretion of *HBV* in cells.

HY-B0255

Adefovir dipivoxil 1 Publications Verification GS 0840	Infection Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Cancer	HBV Reverse Transcriptase Orthopoxvirus Endogenous Metabolite
Adefovir dipivoxil, an adenosine analogue, is an oral proagent of the nucleoside reverse transcriptase inhibitor Adefovir. Adefovir dipivoxil inhibits both the wild type and *HBV* Lamivudine-resistant strains . Adefovir dipivoxil shows anti-orthopoxvirus activity.

HY-N3093

Periglaucine B (+)-Periglaucine B	Structural Classification Alkaloids Pyrrole Alkaloids Source classification Pericampylus glaucus (Lam.) Merr. Plants Menispermaceae	HBV
Periglaucine B ((+)-Periglaucine B) is an alkaloid and an HBsAg inhibitor. Periglaucine B can be isolated from Pericampylus glaucus. Periglaucine B inhibits the secretion of hepatitis B virus (HBV) surface antigen (HBsAg) in Hep G2.2.15 cells with an IC₅₀ of 0.47 mM .

HY-B0150

Nicotinamide Maximum Cited Publications 36 Publications Verification Niacinamide; Nicotinic acid amide	Alkaloids Structural Classification Human Gut Microbiota Metabolites Microorganisms Neurological Disease Classification of Application Fields Source classification Pyridine Alkaloids Endogenous metabolite Disease Research Fields Cancer	Organoid Endogenous Metabolite Sirtuin HBV
Nicotinamide is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC₅₀: 2 μM). Nicotinamide also inhibits SIRT1. Nicotinamide increases cellular NAD₊, ATP, ROS levels. Nicotinamide inhibits tumor growth and improves survival. Nicotinamide also has anti-HBV activity .

HY-B1192

Estradiol benzoate 10+ Cited Publications β-Estradiol 3-benzoate; 17β-Estradiol 3-benzoate	Classification of Application Fields Disease Research Fields Cancer	Estrogen Receptor/ERR HBV Bcl-2 Family
Estradiol benzoate (β-Estradiol 3-benzoate) is a HBx protein inhibitor and inhibits androgen and hepatitis B virus (HBV) transcription, replication. Estradiol benzoate shows antifertility effects, anti- Toxoplasma gondii activity and can improve memory behavior of Ovariectomy (Ovx) female mice .

HY-N3239

Mulberrofuran G	Structural Classification Source classification Phenols Polyphenols Plants Moraceae Morus alba Linn.	NADPH Oxidase HBV
Mulberrofuran G protects ischemic injury-induced cell death via inhibition of NOX4-mediated ROS generation and ER stress . Mulberrofuran G shows moderate inhibiting activity of *hepatitis B virus (HBV)* DNA replication with IC₅₀ of 3.99 μM .

HY-N3094

Periglaucine A	Structural Classification Alkaloids Pyrrole Alkaloids Labiatae Source classification Plants Erigeron breviscapus (Vant.) Hand.-Mazz.	HBV HIV
Periglaucine A, a hasubanane-type alkaloid, can be isolated from Pericampylus glaucus. Periglaucine A can inhibits *HBV* surface antigen (HBsAg) secretion in Hep G2.2.15 cells. Periglaucine A also shows anti-HIV-1 activity in C8166 cells (EC₅₀: 204 μM) .

HY-N0063

Punicalagin 5 Publications Verification	Infection Structural Classification Punica granatum L. Classification of Application Fields Source classification Phenols Polyphenols Metabolic Disease Punicaceae Plants Disease Research Fields	SARS-CoV HBV
Punicalagin is a polyphenol ingredient isolated from Pomegranate (Punica granatum L.) or the leaves of Terminalia catappa L.. Punicalagin is a reversible and non-competitive 3CL ^pro inhibitor and inhibits SARS-CoV-2 replication in vitro. Punicalagin is an anti-hepatitis B virus (HBV) agent and has antioxidant, anti-inflammatory, and anticancer effects. Punicalagin has the potential for the research of COVID-19 .

HY-N6939

Pseudolaric Acid B 1 Publications Verification	Infection Structural Classification Classification of Application Fields Pinaceae Terpenoids Diterpenoids Plants Inflammation/Immunology Disease Research Fields Cancer	HBV Fungal Apoptosis Autophagy Ferroptosis
Pseudolaric Acid B is a diterpene isolated from the root of Pseudolarix kaempferi (pinaceae), has anti-cancer, antifungal, and antifertile activities, and shows immunosuppressive activity on T lymphocytes . Pseudolaric Acid B inhibits hepatitis B virus *(HBV)* secretion through apoptosis and cell cycle arrest. Pseudolaric Acid B induces autophagy .

HY-B0150R

Nicotinamide (Standard) Maximum Cited Publications 36 Publications Verification Niacinamide(Standard); Nicotinic acid amide (Standard)	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Cancer	Endogenous Metabolite Sirtuin
Nicotinamide (Standard) is the analytical standard of Nicotinamide. This product is intended for research and analytical applications. Nicotinamide is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC₅₀: 2 μM). Nicotinamide also inhibits SIRT1. Nicotinamide increases cellular NAD₊, ATP, ROS levels. Nicotinamide inhibits tumor growth and improves survival. Nicotinamide also has anti-HBV activity .

HY-107315

Alisol F 24-acetate	Triterpenes Structural Classification Alisma plantago-aquatica Linn. Terpenoids Source classification Plants Alismataceae	HBV Apoptosis
Alisol F 24-acetate is a triterpene compound that can be isolated from the rhizomes of Alisma orientalis. Alisol F 24-acetate inhibits the secretion of *HBV* surface antigen HBsAg and HBeAg with IC₅₀ values of 7.7 µM and 5.1 µM. Alisol F 24-acetate has proapoptotic activity and can be used for cancer research .

HY-N0639

Punicalin	Structural Classification Punica granatum L. Classification of Application Fields Source classification Phenols Polyphenols Punicaceae Plants Inflammation/Immunology Disease Research Fields	HBV Pyroptosis Carbonic Anhydrase
Punicalin is a species that can be isolated from the leaves of Punica granatum. Punicalin is an active molecule against hepatitis b virus (HBV). Punicalin can induce pyroptosis. Punicalin is a Carbonic anhydrase inhibitor. Punicalin blocks the binding of S-glycoprotein and ACE2 receptors. Pnuicalin has anti-inflammatory, antioxidant and antiviral activity .

Cat. No.	Product Name	Chemical Structure

HY-113904S

(Rac)-Tenofovir-d6

(Rac)-Tenofovir-d₆ is a labelled racemic Tenofovir. Tenofovir (GS 1278) is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B (HBV)[1].

HY-B1826S2

Adefovir-d4
Adefovir-d₄ is the deuterium labeled Adefovir. Adefovir (GS-0393) is an adenosine monophosphate analog antiviral agent that after intracellular conversion to Adefovir diphosphate inhibits HBV DNA polymerase. Adefovir has an IC50 of 0.7 μM against HBV in the HepG2.2.15 cell line. Adefovir has good antiviral activity against several viruses, including HBV and herpesviruses[1][2][3].

HY-156703S

HBV-IN-39-d3

HBV-IN-39-d3 (Example 14) is a deuterated HBV-IN-39 (Example 13). HBV-IN-39 is an HBV inhibitor. HBV-IN-39-d3 has better oral bioavailability than HBV-IN-39 .
HY-13623S

Entecavir-d2

Entecavir-d₂ is the deuterium labeled Entecavir. Entecavir (SQ 34676; BMS 200475) is a potent and selective inhibitor of HBV, with an EC50 of 3.75 nM in HepG2 cell.

HY-B0017S

Telbivudine-d4
Telbivudine-d₄ is deuterium labeled Telbivudine. Telbivudine (Epavudine), an orally active thymidine nucleoside analog, is a potent antiviral inhibitor of hepatitis B virus (HBV) replication[1].

HY-13623S1

Entecavir-13C2,15N
Entecavir- ¹³C₂, ¹⁵N (BMS200475- ¹³C₂, ¹⁵N; SQ34676- ¹³C₂, ¹⁵N) is a ¹³C- and ¹⁵N-labeled Entecavir (HY-13623). Entecavir (SQ 34676; BMS 200475) is a potent and selective inhibitor of *HBV, with an EC₅₀* of 3.75 nM in HepG2 cell.

HY-B0250S1

Lamivudine-13C,15N2,d2
Lamivudine-13C,15N2,d2 (BCH-189-13C,15N2,d2) is a 13C, 15N, and deuterium labeled Lamivudine (HY-B0250). Lamivudine is an orally active and blood-brain barrier permeable nucleoside reverse transcriptase inhibitor (NRTI). Lamivudine inhibits HIV reverse transcriptase 1 and 2 and hepatitis B virus (HBV) reverse transcriptase .

Cat. No.	Product Name		Classification

HY-124614

GLP-26 1 Publications Verification		Alkynes
GLP-26 is a *HBV* capsid assembly modulators (CAM), inhibits HBV DNA replication in Hep AD38 system (IC₅₀=3 nM), and reduces cccDNA by >90% at 1 μM. GLP-26 disrupts the encapsidation of pre-genomic RNA, causes nucleocapsid disassembly and reduces cccDNA pools . GLP-26 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-139262

FNC-TP		Azide
FNC-TP is the intracellular active form of FNC. FNC is a potent *nucleoside reverse transcriptase inhibitor* (NRTI), with antiviral activity on HIV, HBV and HCV** . FNC-TP is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.

HY-19314A

Azvudine hydrochloride RO-0622 hydrochloride; FNC hydrochloride		Azide
Azvudine (RO-0622) hydrochloride is a potent nucleoside reverse transcriptase inhibitor (NRTI), with antiviral activity on HIV, *HBV* and HCV. Azvudine hydrochloride exerts highly potent inhibition on HIV-1 (EC₅₀s ranging from 0.03 to 6.92 nM) and HIV-2 (EC₅₀s ranging from 0.018 to 0.025 nM). Azvudine hydrochloride inhibits NRTI-resistant viral strains . Azvudine (hydrochloride) is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.

HY-19314

Azvudine RO-0622; FNC		Azide
Azvudine (RO-0622) is a potent nucleoside reverse transcriptase inhibitor (NRTI), with antiviral activity on HIV, *HBV* and HCV. Azvudine exerts highly potent inhibition on HIV-1 (EC₅₀s ranging from 0.03 to 6.92 nM) and HIV-2 (EC₅₀s ranging from 0.018 to 0.025 nM). Azvudine inhibits NRTI-resistant viral strains . Azvudine is a click chemistry reagent, itcontains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.

HY-139262A

FNC-TP trisodium		Azide
FNC-TP trisodium is the intracellular active form of FNC. FNC is a potent *nucleoside reverse transcriptase inhibitor* (NRTI), with antiviral activity on HIV, HBV and HCV** . FNC-TP (trisodium) is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

HBV Inhibitor

Inhibitors & Agonists

Peptides

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Natural
Products